Seòmar agus comataidhean

Social Security Scotland is committed to transparency and accountability and routinely publishes statistics on its benefits, including Adult Disability Payment reviews in its quarterly Adult Disability Payment Official Statistics publication.

As of 30 April 2025, 345,955 people had their benefits transferred from Personal Independence Payment to Adult Disability Payment. Social Security Scotland has completed reviews for 142,100 of these awards:

• 20% of awards resulted in an increase in award (28,145 cases)
• 2% resulted in a decrease in award (2,365 cases)
• 79% stayed the same (111,590 cases)

It is not possible to directly calculate the percentage of clients who have had a review, as a small number have had more than one review since their benefit was transferred.

The initial review date for transferred Adult Disability Payment awards is based on the Personal Independence Payment review date set by the Department for Work and Pensions, so many transferred Adult Disability Payment awards are not yet due to be reviewed. The next Adult Disability Payment statistics will be published on 16 September 2025, covering up to 31 July 2025.

Substantial progress has been made by building owners in taking forward the commissioning of Single Building Assessments for these buildings, making use of the financial support available from the Scottish Government. In a small number of cases where building owners/factors are yet to engage in the Single Open Call process we are strongly pressing them to do so and considering what further action may be required. We will publish further information in due course on this cohort of buildings.

All of the Single Building Assessments directly commissioned by the Scottish Government were returned by 31 August. A minority of these have yet to complete the final peer review stage of the process; this is expected to be concluded for all by 19 September.

I most recently met with the Scottish Trades Union Congress, and relevant member trade union representatives, to discuss a range of matters relating to the Tertiary Education and Training (Funding and Governance) (Scotland) Bill and skills reform programme on 24 July 2025.

The Education, Children and Young People Committee took evidence from trade union representatives on the Bill on 21 May 2025. The Scottish Government will carefully consider the Stage 1 report from the Committee and points made in the Stage 1 debate, as well as the views of unions and other stakeholders, before considering what, if any, amendments to lodge for consideration by the Committee or the Parliament.

The Minister, alongside the public bodies impacted by the changes set out in the Bill, remain committed to continued and meaningful engagement with trade unions as the Bill progresses.

The Scottish Government does not hold this data.

Any preparations in relation to the proposals for the opening of a Scottish Government office in Warsaw have been undertaken by officials with the Directorate for Culture and External Affairs as part of normal business.

The opening of a Scottish Government office in Warsaw is currently under review given ongoing budget pressures.

I wrote to Ashley Dalton MP, Parliamentary Under-Secretary of State for Public Health and Prevention at the Department for Health & Social Care (DHSC) on 8 Aprill 2025 in order to outline the Scottish Government’s position on Clauses 2 and 3 of the Rare Cancers Bill.

Over the last year, my officials have been engaging in active conversation with the UK Government and the other devolved nations on the implementation of the provisions of the Bill.

The Scottish Government is committed to increasing the availability of safe and effective medicines that people in Scotland would benefit from. The Scottish Medicines Consortium (SMC) assesses the clinical and cost effectiveness of newly licensed medicines on a once for Scotland basis and publishes advice for Health Boards to consider. It is expected that Health Board Area & Drug and Therapeutics Committees (ADTCs) will consider making an SMC recommended medicine, or an equivalent, available on their local or regional formulary for routine prescribing within 90 days of SMC advice being published.

Health Boards are expected to apply common principles and processes in the introduction of newly licensed medicines to facilitate consistency of approach to local decision-making. The decision to prescribe a medicine, and which medicine to prescribe, is entirely for the clinician in charge of a person’s care, having considered their clinical condition, their safety, and any relevant clinical guidance.

Vorasidenib (Voranigo®) does not currently have a marketing authorisation (sometimes referred to as a licence) from the Medicines and Healthcare products Regulatory Agency (MHRA) which means it cannot be marketed or sold in the UK. The marketing authorisation process involves the MHRA reviewing and assessing the evidence supporting a medicinal product’s quality, safety and efficacy.

As a result, vorasidenib is being offered for a limited time by the pharmaceutical company, Servier, through a free-of-charge (FOC) pharmaceutical company-led early access programme. Health Boards have processes for considering the use of an unlicensed medicine, including through FOC early access programmes, on an individual case-by-case basis where the clinician feels it would benefit an individual. The Scottish Government does not hold data on these decisions.

Individual Health Boards are responsible for decisions on the implementation and availability of medicines in their area. The Scottish Government has committed to investing rebates from the Voluntary Scheme for Branded Medicines Pricing, Access and Growth (VPAG) to fund the New Medicines Fund (NMF), which provides additional top-up funding to territorial Health Boards to support the cost of introducing new medicines. Since 2014/15, £906 million has been made available to Health Boards via the NMF.